PMC:7306567 / 2483-2843 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":7,"end":11},"obj":"Body_part"},{"id":"T5","span":{"begin":301,"end":305},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"s or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-ver"}

{"project":"LitCovid-PubTator","denotations":[{"id":"50","span":{"begin":173,"end":195},"obj":"Disease"},{"id":"51","span":{"begin":253,"end":267},"obj":"Disease"},{"id":"52","span":{"begin":269,"end":271},"obj":"Disease"}],"attributes":[{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D055744"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:D015470"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:D009101"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"s or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-ver"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T23","span":{"begin":173,"end":195},"obj":"Disease"},{"id":"T24","span":{"begin":182,"end":195},"obj":"Disease"},{"id":"T25","span":{"begin":197,"end":199},"obj":"Disease"},{"id":"T26","span":{"begin":253,"end":267},"obj":"Disease"},{"id":"T27","span":{"begin":259,"end":267},"obj":"Disease"},{"id":"T28","span":{"begin":269,"end":271},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0010643"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0010643"}],"text":"s or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-ver"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T16","span":{"begin":5,"end":11},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T17","span":{"begin":301,"end":305},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"s or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-ver"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":197,"end":199},"obj":"Chemical"},{"id":"T7","span":{"begin":269,"end":271},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_74062"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_73770"}],"text":"s or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-ver"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":253,"end":267},"obj":"Phenotype"},{"id":"T10","span":{"begin":269,"end":271},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002488"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002488"}],"text":"s or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-ver"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T32","span":{"begin":5,"end":11},"obj":"CL:0000084"},{"id":"T33","span":{"begin":110,"end":127},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T17383","span":{"begin":5,"end":11},"obj":"CL:0000084"},{"id":"T96288","span":{"begin":110,"end":127},"obj":"CHEBI:35705;CHEBI:35705"}],"text":"s or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-ver"}

{"project":"2_test","denotations":[{"id":"32572532-25354514-47963394","span":{"begin":137,"end":138},"obj":"25354514"},{"id":"T48775","span":{"begin":137,"end":138},"obj":"25354514"}],"text":"s or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-ver"}